SI1854477T1 - Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj - Google Patents

Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj

Info

Publication number
SI1854477T1
SI1854477T1 SI200731849A SI200731849A SI1854477T1 SI 1854477 T1 SI1854477 T1 SI 1854477T1 SI 200731849 A SI200731849 A SI 200731849A SI 200731849 A SI200731849 A SI 200731849A SI 1854477 T1 SI1854477 T1 SI 1854477T1
Authority
SI
Slovenia
Prior art keywords
treatment
plasma kallikrein
ophthalmic disorders
inhibiting plasma
peptides inhibiting
Prior art date
Application number
SI200731849A
Other languages
English (en)
Inventor
Pierre Belichard
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38573251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1854477(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of SI1854477T1 publication Critical patent/SI1854477T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
SI200731849A 2006-03-16 2007-03-13 Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj SI1854477T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26
EP07005182.6A EP1854477B9 (en) 2006-03-16 2007-03-13 Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.

Publications (1)

Publication Number Publication Date
SI1854477T1 true SI1854477T1 (sl) 2017-01-31

Family

ID=38573251

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731849A SI1854477T1 (sl) 2006-03-16 2007-03-13 Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj

Country Status (5)

Country Link
EP (2) EP1854477B9 (sl)
CY (2) CY1118767T1 (sl)
DK (1) DK2374472T3 (sl)
PL (1) PL2374472T3 (sl)
SI (1) SI1854477T1 (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012320407B2 (en) 2011-10-07 2017-04-20 Bicyclerd Limited Modulation of structured polypeptide specificity
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38A (en) 1836-10-04 Horizontal boot-clamp
US4079A (en) 1845-06-10 Corn-shei
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6087473A (en) 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
US6596296B1 (en) 1999-08-06 2003-07-22 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2372978T3 (es) * 2002-06-07 2012-01-30 Dyax Corp. Polipéptido con dominio de kunitz modificado.
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
EP1858542A4 (en) 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHODS FOR TREATING VASCULAR PERMEABILITY
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein

Also Published As

Publication number Publication date
EP2374472A2 (en) 2011-10-12
PL2374472T3 (pl) 2018-11-30
DK2374472T3 (en) 2018-08-13
EP1854477A3 (en) 2008-06-11
EP2374472B9 (en) 2019-06-12
EP2374472A3 (en) 2012-05-16
CY1118767T1 (el) 2017-07-12
EP1854477B1 (en) 2016-08-03
CY1121044T1 (el) 2019-12-11
EP2374472B1 (en) 2018-05-02
EP1854477A2 (en) 2007-11-14
EP1854477B9 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
LT1854477T (lt) Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui
IL191283A (en) Compositions for treating eye irregularities
ZA200800464B (en) Peptides for use in the treatment of obesity
IL193747A0 (en) New therapeutic combinations for the treatment of depression
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB0602178D0 (en) Therapeutic treatment
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
ZA200901523B (en) Use of extracts for the treatment of viral disorders
GB0608655D0 (en) Therapeutic Treatment
IL196667A (en) Use of peptides to prepare a drug to treat inflammation
GB0523961D0 (en) The treatment of ophthalmic diseases
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
EP2225196A4 (en) CYSTONE PROTEASE INHIBITOR FOR THE TREATMENT OF PARASITIC DISEASES
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
GB0610909D0 (en) Therapeutic treatment
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
SI1854477T1 (sl) Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
ME01951B (me) Upotreba agomelatina za dobijanje lekova namenjenih tretmanu bipolarnih poremećaja
GB0523964D0 (en) The treatment of ophthalmic diseases
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
GB0602857D0 (en) The treatment of sialorrhoea
GB0610376D0 (en) Therapeutic treatment
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis